US Biotech Says Drug Thwarted Muscle Loss in Wegovy Patients

A US biotech’s experimental drug helped prevent muscle loss in patients taking Novo Nordisk A/S’s Wegovy in a study whose results caused the stock to slump before US exchanges opened.

Older patients taking Veru Inc’s experimental treatment enobosarm with Wegovy lost on average 1.2% of lean body mass after 16 weeks, compared with a 4.1% decline for volunteers just taking Wegovy and a placebo, the US biotech said Monday, citing initial trial results.